Valuation : Gabather AB

Market Cap 20.88M 2.18M 1.88M 1.76M 1.61M 3.03M 208M 3.04M 8.15M 105M 8.18M 8M 348M P/E 2024
-1.07x
P/E 2025 -1.13x
Enterprise Value 17.74M 1.85M 1.59M 1.49M 1.36M 2.57M 177M 2.58M 6.92M 89.27M 6.95M 6.8M 296M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
90.95%
Yield 2024 *
-
Yield 2025 -
1 day+1.18%
1 week+6.88%
Current month+14.77%
1 month+22.14%
3 months-8.56%
6 months-5.00%
Current year+24.82%
1 week 0.03
Extreme 0.0306
0.04
1 month 0.03
Extreme 0.0276
0.04
Current year 0.02
Extreme 0.023
0.1
1 year 0.02
Extreme 0.023
0.1
3 years 0.02
Extreme 0.023
4.2
5 years 0.02
Extreme 0.023
6.55
10 years 0.02
Extreme 0.023
62.8
Manager TitleAgeSince
Chief Executive Officer - 01/10/2018
Chief Operating Officer - 01/01/2018
Chief Tech/Sci/R&D Officer - 01/01/2018
Director TitleAgeSince
Director/Board Member - 01/09/2014
Director/Board Member 60 03/11/2014
Chairman - 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.18%+6.88%-2.84%-98.65% 2.18M
-1.59%-3.35%+52.37%+93.70% 69.54B
-1.34%-0.75%+48.21%+91.86% 64.97B
+0.30%-0.69%+52.56%+10.23% 26.51B
-2.35%-5.75%-12.90%+448.54% 25.89B
-8.37%-12.43%+2.08%-16.71% 25.64B
-0.96%+10.36%+283.06%+436.50% 20.22B
-0.51%+0.23%+35.77%-18.70% 19.98B
-1.91%-4.37%+13.28%+535.19% 15.69B
-1.47%+0.68%+45.51%+143.08% 13.49B
Average -1.70%-1.04%+51.71%+162.50% 28.19B
Weighted average by Cap. -1.93%-1.50%+53.73%+151.51%

Financials

2024 2025
Net sales - -
Net income -7.75M -809K -697K -653K -597K -1.12M -77.3M -1.13M -3.02M -39.02M -3.04M -2.97M -129M -4.65M -485K -418K -392K -358K -674K -46.38M -676K -1.82M -23.41M -1.82M -1.78M -77.64M
Net Debt -878K -91.6K -78.93K -74K -67.55K -127K -8.75M -128K -343K -4.42M -344K -336K -14.65M -3.14M -328K -283K -265K -242K -456K -31.34M -457K -1.23M -15.82M -1.23M -1.2M -52.45M
Logo Gabather AB
Gabather AB is a Sweden-based company engaged pharmaceutical industry. The Company develops drug candidates for the treatment of several diseases originating in the central nervous system (CNS). The Company mainly focuses on anti-psychotics, anti-depressants and anxiolytics, analgesics, as well as conginition-enhancing treatments, including Alzheimer’s disease.
Employees
2
Date Price Change Volume
28/08/26 SEK 0.0342 +1.18% 3,119,266
27/08/26 SEK 0.0338 -2.87% 5,594,904
26/08/26 SEK 0.0348 +12.99% 3,176,265
25/08/26 SEK 0.0308 0.00% 111,677
24/08/26 SEK 0.0308 -3.75% 1,906,007
  1. Stock Market
  2. Stocks
  3. GABA Stock